United States Federal Circuit

Reset A A Font size: Print

Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., 17-2078

Affirmed that a pharmaceutical company's patent claims in a multiple sclerosis drug were invalid for obviousness. Several competitors seeking to market a generic version of the same drug raised the issue of obviousness when the company sued them for infringement. In a 2-1 decision, the Federal Circuit affirmed that the patent claims in question were invalid.

Appellate Information

  • Decided
  • Published 2018/09/10


  • Taranto


  • United States Federal Circuit


FindLaw Career Center

    Select a Job Title

      Post a Job  |  Careers Home

    View More